Nadim Mahmud1, Binu John2,3, Tamar H Taddei4,5, David S Goldberg1,6. 1. Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Virginia Commonwealth University, Richmond, Virginia. 3. McGuire VA Medical Center, Richmond, Virginia. 4. Division of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut. 5. VA Connecticut Healthcare System, West Haven, Connecticut. 6. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Although liver transplantation may potentially cure hepatocellular carcinoma (HCC), the risk of HCC recurrence is 8%-20% at five years post-transplant. Pre-transplant alpha-fetoprotein (AFP) is a predictor of HCC recurrence, but it is unknown if pre-transplant AFP also predicts survival in patients with recurrence. METHODS: We performed a retrospective cohort study using the United Network for Organ Sharing (UNOS) database between 2002 and 2016. We identified adult transplant recipients with HCC recurrence after liver transplantation for HCC and used Cox regression to compare patient survival among different maximum pre-transplant AFP levels. RESULTS: The cohort (N = 1164) was primarily male, white, and with hepatitis C liver disease. The median time to HCC recurrence was 11.6 months (interquartile range 6.1-26.3). In Cox regression analysis, increasing pre-transplant AFP was associated with poorer survival when adjusting for age, pre-transplant model for end-stage liver disease (MELD), and time to HCC recurrence. For example, patients with pre-transplant AFP ≥500ng/mL had a 1.6-fold higher risk of death versus those with AFP ≤20ng/mL (P < 0.001). CONCLUSION: Pre-transplant AFP is independently associated with survival in patients with HCC recurrence. These findings further contextualize the importance of pre-transplant AFP in liver transplantation and may improve prognostication for patients with HCC recurrence.
BACKGROUND: Although liver transplantation may potentially cure hepatocellular carcinoma (HCC), the risk of HCC recurrence is 8%-20% at five years post-transplant. Pre-transplant alpha-fetoprotein (AFP) is a predictor of HCC recurrence, but it is unknown if pre-transplant AFP also predicts survival in patients with recurrence. METHODS: We performed a retrospective cohort study using the United Network for Organ Sharing (UNOS) database between 2002 and 2016. We identified adult transplant recipients with HCC recurrence after liver transplantation for HCC and used Cox regression to compare patient survival among different maximum pre-transplant AFP levels. RESULTS: The cohort (N = 1164) was primarily male, white, and with hepatitis C liver disease. The median time to HCC recurrence was 11.6 months (interquartile range 6.1-26.3). In Cox regression analysis, increasing pre-transplant AFP was associated with poorer survival when adjusting for age, pre-transplant model for end-stage liver disease (MELD), and time to HCC recurrence. For example, patients with pre-transplant AFP ≥500ng/mL had a 1.6-fold higher risk of death versus those with AFP ≤20ng/mL (P < 0.001). CONCLUSION: Pre-transplant AFP is independently associated with survival in patients with HCC recurrence. These findings further contextualize the importance of pre-transplant AFP in liver transplantation and may improve prognostication for patients with HCC recurrence.
Authors: J Figueras; E Jaurrieta; C Valls; E Ramos; T Serrano; A Rafecas; J Fabregat; J Torras Journal: J Am Coll Surg Date: 2000-05 Impact factor: 6.113
Authors: Gia L Tyson; Zhigang Duan; Jennifer R Kramer; Jessica A Davila; Peter A Richardson; Hashem B El-Serag Journal: Clin Gastroenterol Hepatol Date: 2011-08-04 Impact factor: 11.382
Authors: Elizabeth A Pomfret; Kenneth Washburn; Christoph Wald; Michael A Nalesnik; David Douglas; Mark Russo; John Roberts; David J Reich; Myron E Schwartz; Luis Mieles; Fred T Lee; Sander Florman; Francis Yao; Ann Harper; Erick Edwards; Richard Freeman; John Lake Journal: Liver Transpl Date: 2010-03 Impact factor: 5.799
Authors: Shaheed Merani; Pietro Majno; Norman M Kneteman; Thierry Berney; Philippe Morel; Gilles Mentha; Christian Toso Journal: J Hepatol Date: 2011-02-18 Impact factor: 25.083
Authors: P Tangkijvanich; N Anukulkarnkusol; P Suwangool; S Lertmaharit; O Hanvivatvong; P Kullavanijaya; Y Poovorawan Journal: J Clin Gastroenterol Date: 2000-12 Impact factor: 3.062
Authors: Sasan Roayaie; Jonathan D Schwartz; Max W Sung; Sukru H Emre; Charles M Miller; Gabriel E Gondolesi; Nancy R Krieger; Myron E Schwartz Journal: Liver Transpl Date: 2004-04 Impact factor: 5.799
Authors: Volkan Ince; Brian I Carr; Harika Gozukara Bag; Veysel Ersan; Sertac Usta; Cemalettin Koc; Fatih Gonultas; Baris Kemal Sarici; Serdar Karakas; Koray Kutluturk; Adil Baskiran; Sezai Yilmaz Journal: World J Gastrointest Surg Date: 2020-12-27
Authors: Wojciech Andrzej Straś; Dariusz Wasiak; Beata Łągiewska; Olga Tronina; Marta Hreńczuk; Joanna Gotlib; Wojciech Lisik; Piotr Małkowski Journal: Ann Transplant Date: 2022-01-26 Impact factor: 1.530
Authors: Hugo Pinto-Marques; Joana Cardoso; Sílvia Silva; João L Neto; Maria Gonçalves-Reis; Daniela Proença; Marta Mesquita; André Manso; Sara Carapeta; Mafalda Sobral; Antonio Figueiredo; Clara Rodrigues; Adelaide Milheiro; Ana Carvalho; Rui Perdigoto; Eduardo Barroso; José B Pereira-Leal Journal: Ann Surg Date: 2022-08-01 Impact factor: 13.787
Authors: Jae H Yoon; Young J Goo; Chae-Jun Lim; Sung K Choi; Sung B Cho; Sang S Shin; Chung H Jun Journal: World J Gastroenterol Date: 2020-08-28 Impact factor: 5.742